NEW YORK (GenomeWeb News) – GeneNews said today that under a new agreement drugmaker Eli Lilly will have select access to its osteoarthritis genomic biomarker program.

Toronto-based GeneNews specializes in using functional genomics for biomarker-based early disease diagnosis.

GeneNews Lead Director and Interim CEO Heiner Dreismann said in statement that the firm's Sentinel Principle technology "can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.